Literature DB >> 11124127

Endothelin and nitric oxide mediate reduced myogenic reactivity of small renal arteries from pregnant rats.

R E Gandley1, K P Conrad, M K McLaughlin.   

Abstract

We tested the hypothesis that endothelin acting through the endothelial ET(B) receptor subtype and the nitric oxide (NO) pathway accounts for reduced myogenic reactivity of the renal resistance vasculature during pregnancy. Small renal arteries (100-200 microm) were isolated from virgin and midterm pregnant rats when gestational renal hyperfiltration and vasodilation are maximal in this species. Myogenic reactivity (the adjustment of arterial diameter in response to a change in transmural pressure) was assessed with a pressurized myograph system. A rapid increase in transmural pressure from 60 to 80 mmHg resulted in a 2.4% diameter increase in vessels from virgin compared with an 8.1% increase in arteries from midgestation rats (n = 8 each, P < 0.05). Thus myogenic reactivity is markedly reduced during pregnancy. Incubation with the NO synthase inhibitors, an ET(B) receptor subtype antagonist (RES-701-1), the nonselective ET(A/B) receptor blocker (SB-209670), or endothelial removal abrogated the reduced myogenic reactivity of vessels from gravid rats without affecting myogenic reactivity in arteries from virgin animals. Thus the endothelium mediates the reduced myogenic reactivity of small renal arteries of midgestation rats most likely through the ET(B) receptor subtype and NO pathway.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11124127     DOI: 10.1152/ajpregu.2001.280.1.R1

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  30 in total

1.  Relaxin is essential for renal vasodilation during pregnancy in conscious rats.

Authors:  J Novak; L A Danielson; L J Kerchner; O D Sherwood; R J Ramirez; P A Moalli; K P Conrad
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

2.  Chronic hypoxia suppresses pregnancy-induced upregulation of large-conductance Ca2+-activated K+ channel activity in uterine arteries.

Authors:  Xiang-Qun Hu; Daliao Xiao; Ronghui Zhu; Xiaohui Huang; Shumei Yang; Sean M Wilson; Lubo Zhang
Journal:  Hypertension       Date:  2012-06-04       Impact factor: 10.190

Review 3.  Effects of relaxin on arterial dilation, remodeling, and mechanical properties.

Authors:  Kirk P Conrad; Sanjeev G Shroff
Journal:  Curr Hypertens Rep       Date:  2011-12       Impact factor: 5.369

4.  Impact of endothelin A receptor antagonist selectivity in chronic nitric oxide synthase inhibition-induced fetal growth restriction in the rat.

Authors:  Mark G Neerhof; Sylvia Synowiec; Saira Khan; Larry G Thaete
Journal:  Hypertens Pregnancy       Date:  2010       Impact factor: 2.108

Review 5.  Renal autoregulation in health and disease.

Authors:  Mattias Carlström; Christopher S Wilcox; William J Arendshorst
Journal:  Physiol Rev       Date:  2015-04       Impact factor: 37.312

Review 6.  Plasticity of the Maternal Vasculature During Pregnancy.

Authors:  George Osol; Nga Ling Ko; Maurizio Mandalà
Journal:  Annu Rev Physiol       Date:  2019-02-10       Impact factor: 19.318

7.  Pregnancy causes diminished myogenic tone and outward hypotrophic remodeling of the cerebral vein of Galen.

Authors:  Anne-Eva van der Wijk; Malou P H Schreurs; Marilyn J Cipolla
Journal:  J Cereb Blood Flow Metab       Date:  2013-01-02       Impact factor: 6.200

Review 8.  Maternal vasodilation in pregnancy: the emerging role of relaxin.

Authors:  Kirk P Conrad
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-05-25       Impact factor: 3.619

9.  GPCRs as potential therapeutic targets in preeclampsia.

Authors:  Jt McGuane; Kp Conrad
Journal:  Drug Discov Today Dis Models       Date:  2012-07-12

Review 10.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.